Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.22 CAD | +8.29% | +7.77% | -17.78% |
17/04 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
17/04 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 143M 196M 11.96B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.07% |
1 day | +8.29% | ||
1 week | +7.77% | ||
Current month | +0.91% | ||
1 month | +1.83% | ||
3 months | -22.65% | ||
6 months | +15.62% | ||
Current year | -17.78% |
Managers | Title | Age | Since |
---|---|---|---|
William Radvak
FOU | Founder | 61 | 19/17/19 |
Michael Kelly
CEO | Chief Executive Officer | 59 | 10/23/10 |
Bill Adams
DFI | Director of Finance/CFO | 62 | 24/20/24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randall Kaye
BRD | Director/Board Member | 62 | 28/20/28 |
Brian Bayley
BRD | Director/Board Member | 71 | 16/18/16 |
William Radvak
FOU | Founder | 61 | 19/17/19 |
Date | Price | Change | Volume |
---|---|---|---|
03/24/03 | 2.22 | +8.29% | 172 539 |
01/24/01 | 2.05 | -2.38% | 58,205 |
30/24/30 | 2.1 | +1.94% | 140,868 |
29/24/29 | 2.06 | -2.37% | 56,626 |
26/24/26 | 2.11 | +4.46% | 83,425 |
Delayed Quote Toronto S.E., May 03, 2024 at 12:26 am IST
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.78% | 104M | |
+29.05% | 42.68B | |
-3.02% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.45% | 24.94B | |
-20.71% | 18.96B | |
+28.63% | 12.3B | |
-2.34% | 11.95B | |
-1.53% | 11.55B |
- Stock Market
- Equities
- NGEN Stock